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Introduction
Pleural effusion is a common complication of systemic 
or localized diseases and affects about 3000 people per 
million populations each year. It is a common manifestation 
of various malignancies (Cox and Katlic, 2015; Haridas, 
Suraj, Rajagopal, James and Chetambath, 2014). It is 
significantly important to correctly differentiate between 
benign and malignant pleural effusions. A malignant 
pleural effusion represents an advanced malignancy 
disease which is associated with high mortality; while 
benign cases have a high chance to be cured if an accurate 
diagnosis can be made and appropriate treatment given 
(Azimi, Rezadoost, Nadoushan and Davati, 2012; 
Nam, 2014) . Pleural fluid aspiration and cytological 
examination is currently the main diagnostic method for 
determining pleural fluid characteristics which at ideal 
settings has a sensitivity of 60% (Sriram et al., 2011). 
Although the presence of tumor cells in pleural effusion 
is a diagnostic marker of malignant pleural effusion, the 
probability of finding them is low. It is more likely to find 
the factors secreted by tumor in the pleural fluid or serum 
(M Li et al., 2014; Xu, Yu, Zhan and Zhang, 2014). 
Neuron-Specific Enolase (NSE) is the γ-subunit of 
the glycolytic enolase enzyme which is secreted from 
neuroendocrine cells as well as neurogenic tumors. NSE 
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has been recognized as a biomarker for small cell lung 
carcinoma (Ravibabu, Barman, and Rajmohan, 2015; 
Tiseo et al., 2008). Cancer Antigen 15-3 (CA 15-3) is 
another tumor marker that is widely used for diagnosis 
and prognosis of malignancies such as breast cancer (Li, 
Chen, Su, Song, and Gong, 2014; Lucarelli et al., 2014). 
The diagnostic values of these two tumor markers in 
distinguishing the nature of pleural effusion have been 
investigated in some studies and mixing results have 
been reported. This study assessed the diagnostic values 
of these two tumor markers in differentiating the nature 
of the pleural fluid.
Materials and Methods
Study Participants
In this cross-sectional investigation, 93 patients 
admitted to the pulmonology ward in Kashan Shahid 
Beheshti Hospital during fall and winter of 2013-2014, 
whose pleural effusions were proven through clinical 
examinations and imaging findings such as chest X-ray or 
chest CT scanning, were evaluated. Patients who received 
anticoagulants, had platelet counts less than 50000 per 
milliliter or had an INR value greater than 2 were excluded 
from the study. Patients were allocated by a nonrandom 
process and all patients were entered into the study after 
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providing a written informed consent to participate.
Pleural Effusion and Blood Sampling
Ultrasound guidance was used to mark an appropriate 
site where fluid was most likely to be obtained. After skin 
disinfection and local anesthesia, a needle was introduced 
into the intercostal space parallel to the upper border of 
the rib below the chosen intercostal space. Following 
catheter placement into the pleural space 10 and 20 mL 
samples of the pleural fluid were separately withdrawn in 
pre-heparinized syringes and the samples were sent to the 
laboratory for cytological examination and measuring the 
tumor markers levels. Simultaneous 5 mL blood samples 
from a peripheral vein were obtained for the measurement 
of the serum levels of the tumor markers. All samples were 
immediately centrifuged at 3000 rpm and were then stored 
at -20°C until being used.
Cytological Assesment
Cytologic preparations were made by direct smearing 
of fluid sediment or by cytocentrifugation. The smears 
were either fixed in 95% ethanol or air-dried. Fixed 
smears were stained by the Papanicolaou technique, with 
hematoxylin and eosin, and air-dried smears were stained 
with the Romanowsky technique. Red blood cells in 
bloody smears were lysed by fixing in Carnoy solution for 
3-5 min. A Ficoll- Hypaque solution was used to separate 
red blood cells from nucleated cells in a markedly bloody 
specimen. The cell blocks obtained by centrifugation were 
fixed in formalin and processed as an issue sample and cell 
block sections were stained with hematoxylin and eosin 
(Kashani et al., 2013; Nikzad, Kashani, Kabir-Salmani, 
Akimoto and Iwashita, 2013).
Tumor Markers Measurement
Serum and pleural levels of NSE and CA 15-3 were 
measured using immunoenzyme assay kits manufactured 
by DiaMetra incorporation, Italy. Malignant effusions 
were diagnosed if malignant cells or tissues were found 
in the pleural fluid or biopsies. Pleural effusions were 
classified as malignant if the effusions occurred in a patient 
with a known active malignancy until another cause was 
identified.
Statistical analysis 
Results from this study were analyzed using SPSS 
software version 16 (Hosseini, Moniri, Goli, and Kashani, 
2016; Sharif et al., 2016). Nonparametric tests were used 
for statistical analysis because the data did not follow a 
normal distribution. Mann-Whitney U test was used for 
comparisons of differences between the two groups. To 
find the optimal diagnostic cut-off points of the studied 
tumor markers Receiver operating characteristic (ROC) 
curve was plotted. The results are reported as percentages 
or mean ± standard deviation. The significance level of p 
was less than 0.05.
Results
Of the all 93 studied patients, 64 (68.8%) were men. 
The mean age of the studied patients was 70.1±16.8. 44 
effusions (47.3%) were reported malignant and of these 
26 (59.1%) were men. The mean age of patients with 
malignant effusions was 66.6±16.6 years versus 73.4±16.5 
years in patients with a benign pleural effusion. Pleural 
effusion causes on the basis of its nature are shown in 
Table 1.
The average levels of the studied tumor markers 
were significantly higher in cases of malignant effusions 
compared to the benign ones. The mean levels of the 
measured tumor markers in the serum and pleural fluids 
of patients are shown in Table 2. 
ROC curve analysis (Figure 1) showed that the largest 
Figure 1. Receiver Operating Characteristics (ROC) 
Curves for All the Investigated Parameters
Causes Number Percent
Malignant
     Lung cancer 12 12.9
     Colon cancer 8 8.6
     Unknown origin 4 4.3
     Breast cancer 3 3.2
     Lymphoma 3 3.2
     Bladder cancer 3 3.2
     Prostat cancer 3 3.2
     Gastric cancer 2 2.2
     Pancreas cancer 2 2.2
     Soft tissue malignancy 2 2.2
     Hepatic cancer 1 1.1
     Parotid cancer 1 1.1
Benign
     Congestive heart failure 13 14.0
     Trauma 10 10.8
     Renal disease 9 9.7
     Empyema 8 8.6
     Tuberculosis 3 3.2
     Rheumatologic disease 2 2.2
     Pulmonary embolism 2 2.2
     Hepatic cirrhosis 2 2.2
     Total 93 100.0
Table 1. Causes of Pleural Effusion
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effusion caused by tuberculosis, it was found that the 
mean serum and pleural levels of NSE was significantly 
higher in malignant effusions compared with the benign 
ones. Despite the fact that NSE is usually produced and 
secreted by SCLC cells, higher serum and pleural NSE 
levels have also been reported with NSCLC compared to 
the benign conditions (Alam, Baig, Mahmood, Asghar, and 
Ali, 2010). Lin et al., (2010) investigating tumor markers 
levels in 62 patients with malignant pleural effusion and 48 
patients with benign pleural effusion found that the levels 
of NSE in serum and pleural effusion in malignant groups 
were significantly higher. In another study performed by 
Liu et al 99 patients with malignant pleural effusion caused 
by lung cancer (SCLC, adenocarcinoma and squamous cell 
carcinoma) were compared with 37 patients with benign 
pleural effusion and 35 healthy persons. They found that 
the levels of NSE in serum and pleural effusion of all the 
malignant groups were significantly higher than those in 
the benign groups. No significant differences were seen 
between the benign ones and the healthy ones (Liu, Yu, 
and Lin, 2006) 17. Similar results have been obtained from 
other studies (Lee and Chang, 2005; Menard, Dousset, 
Jacob, and Martinet, 1993; Wang, Zhang, Gu, Ma, and 
Jia, 2002). Patients with malignant pleural effusions with 
non-pulmonary origins were also enrolled in our study. 
Based on the present study’s results and past findings, it 
can be concluded that measuring serum and pleural NSE 
levels is a useful test not only in diagnosing malignant 
pleural effusions due to primary lung tumors, but also for 
malignant effusions secondary to extra pulmonary cancers.
In present study, using cut-off point of 11.3ng/ml 
for serum NSE the sensitivity and the specificity were 
75% and 69.4%, respectively. Also, the sensitivity and 
the specificity of pleural NSE were 75% and 73.5% 
respectively using the cut-off point of 5ng/ml. In the study 
by Lee et al., (2005) using the cut-off point of 20ng/ml for 
pleural NSE the sensitivity and the specificity were 36% 
and 94% respectively. In Ghayumi et al., (2005) study, 
considering a cut-off point of 5.21ng/ml for pleural NSE 
the overall sensitivity, specificity, positive predictive value 
and negative predictive value were as follows: 68.4%, 
75%, 74.3% and 69.2% respectively. For serum NSE with 
the cut-off point of 10.36, sensitivity and specificity were 
38.9% and 63.6% respectively. Positive predictive value 
was 51.1% and negative predictive value was 46.2% . 
Kuralay et al., (2000) using the cut-off point of 8.7ng/ml 
area under the curve belongs to the pleural levels of NSE 
(0.81, 95% CI= 0.72-0.9) and the least area under the 
curve represents the serum levels of CA 15-3 (0.69, 95% 
CI= 0.58-0.8).
Of the studied markers, the pleural level of NSE is the 
most accurate which is associated with a high sensitivity 
and specificity. Among all four studied markers the 
lowest accuracy belongs to the serum level of CA 15-3, 
which has the lowest sensitivity and specificity as well. 
The diagnostic value of the combination of these two 
tumor markers was also calculated. If at least two factors 
had levels above the cut-off point, the results would be 
considered positive. Results are shown in Table 3.
Discussion
Because of the significant differences in treatment 
and prognosis, the distinction between malignant and 
benign pleural effusions is important but challenging. 
About 12 to 24% of all pleural effusions are malignant 
(Heffner, 2008). Malignant pleural effusions usually occur 
in patients already known to have cancer but in one third 
of the cases, pleural effusion is the first manifestation 
of cancer (Froudarakis, 2008; Yamamuro et al., 2007). 
Thoracocentesis is a safe and simple procedure to 
obtain the pleural fluid. In the past two decades, due 
to non-invasiveness, there has been growing interest in 
the use of tumor markers for the diagnosis of malignant 
pleural effusions.
In this study it was found that malignant pleural 
effusions can be diagnosed using the serum and pleural 
levels of NSE. In one study by Alam et al which comprised 
33 patients with pleural effusions due to Small Cell Lung 
Carcinoma (SCLC) and Non-Small Cell Lung Carcinoma 
(NSCLC) and 30 other patients with a benign pleural 
Tumor marker Malignant 
(n=44)
Benign 
(n=49)
P value
Serum CA 15-3 58.7±80.5 17.9±11.4 0.002
Pleural CA 15-3 87.4±197.2 9.4±8.1 <0.001
Serum NSE 39.9±41.1 14.5±18.9 <0.001
Pleural NSE 24.9±35.1 4.0±3.9 <0.001
Table 2. The Mean Serum and Pleural Levels of NSE 
and CA 15-3 on The Basis of Pleural Fluid Nature 
(Mean±SD)
* CA-125, (U/ml); NSE, (μg/ml)
Cut-off Sensitivity% Specificity% PPV% NPV% Accuracy%
Serum CA 15-3 13.9 70.4 49.0 55.4 64.9 59.1
Pleural CA 15-3 6.68 79.5 49.0 58.3 72.7 63.4
Serum NSE 11.3 75.0 69.4 68.7 75.5 72.0
Pleural NSE 5.0 75.0 73.5 71.7 76.6 74.2
CA 15-3 (S+P) 68.2 63.3 62.5 68.9 65.6
NSE (S+P) 59.1 89.8 83.9 71.0 75.3
CA 15-3 (S)+ NSE (S) 47.7 85.7 75.0 64.6 67.7
CA 15-3 (P)+ NSE (P) 61.4 73.7 77.1 70.7 73.1
All markers 93.2 44.9 60.3 88 67.7
Table 3. Characteristics of Tumor Markers in Patients with Pleural Effusion
PPV, Positive Predictive Value; NPV, Negative Predictive Value; S, Serum; P, Pleural
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reported a sensitivity of 100% and a specificity of 95%. 
Considering these results from the present and the past 
studies as a whole it is seen that with different cut-off 
points this test will have a high specificity, thus it can be 
used to rule out malignant effusions with an acceptable 
certainty. 
Our results imply that the serum and the pleural 
levels of CA 15-3 have a significant association with the 
malignant nature of the pleural effusions. Shitrit et al 
assessing 44 cases of malignant effusions and comparing 
them with 72 cases of non-malignant effusions found that 
the pleural levels of CA 15-3 in the malignant cases is 
significantly higher than the controls (Shitrit, Zingerman, 
Shitrit, Shlomi, and Kramer, 2005). In the study by Alatas 
et al., (2001) the Pleural and the serum levels of CA 15-3 
were assayed in 44 patients with malignant and 30 with 
benign effusions and CA 15-3 was shown to higher in 
malignant ones and there was a statistical association 
between CA 15-3 and the nature of the effusions. Similar 
results have been observed by other studies (Ghosh et 
al., 2013; Hernández et al., 2002; Miedouge et al., 1999; 
Romero et al., 1996).
In this study considering the cut-off point of 13.9ng/
ml for serum CA 15-3 the calculated sensitivity and 
specificity were 70.4% and 49% respectively. Likewise 
using the cut-off points of 6.68ng/ml for pleural CA 15-3 
the sensitivity and the specificity were found to be 79.5% 
and 49% respectively. Alatas et al., (2001) considering 
the cut-off point of 20ng/ml for serum CA 15-3 have 
reported a sensitivity of 86% and a specificity of 67%. 
Also in the cut-off point of 14ng/ml for pleural CA 15-3 
the calculated sensitivity and specificity were 80 and 
93% respectively. Two separate studies have reported the 
sensitivities of 48 and 97% and the specificities of 100 and 
97% respectively for the diagnosis of malignant effusions 
(Gaspar, De Miguel, Díaz, and Diez, 2008; Shimokata et 
al., 1988). According to the results of the present study 
it seems that this factor has a good diagnostic accuracy 
for the distinction between the malignant and the benign 
pleural effusions.
Our results showed that the co-measurement of these 
two factors will change the diagnostic accuracy. Previous 
studies have shown that measuring the combination 
of these factors will enhance the sensitivity and the 
specificity of the diagnosis (Alataş et al., 2001; Gaspar 
et al., 2008; Miedouge et al., 1999). Co-measurement of 
all 4 factors compared to measuring only the serum or the 
pleural levels of NSE decreased the accuracy but increased 
its sensitivity. It appears that the co-measurement of the 
studied factors does not improve the diagnosis of the 
pleural effusion nature.
The current study indicated that measuring NSE and 
CA 15-3 tumor markers is a suitable method to distinguish 
the nature of the pleural effusion and NSE pleural levels 
had the highest diagnostic accuracy.
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